Axsome Therapeutics Initiates FOCUS-3 Phase 3 Trial of Solriamfetol in Adolescents with Attention Deficit Hyperactivity Disorder (ADHD)

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/18/2026

1. SPY
2. XENE
3. NUE
4. HUBS
5. RTB
6. ONON
7. AAPL
8. TRMD
9. ACN
10. AZN

Go back to Axsome Therapeutics Initiates FOCUS-3 Phase 3 Trial of Solriamfetol in Adolescents with Attention Deficit Hyperactivity Disorder (ADHD)
(NASDAQ: AXSM) Delayed: 207.78 -6.5 (3.03%)
Previous Close $214.28    52 Week High $15.74 
Open $212.05    52 Week Low $5.37 
Day High $213.27    P/E N/A 
Day Low $206.92    EPS $0.00 
Volume 869,302